GlassScriptPhysician profile
Linda Hale
NPI 1588791909
$2,727.86
in general payments reported to CMS, 2019-2025
27 companies · $629 in 2025
The $629 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $624 · 2023: $411 · 2024: $564 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.23 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.16 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $311.45 | 2021-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $287.84 | 2022-2025 | |
| Abbott Laboratories | $245.27 | 2021-2025 | Cardiomems |
| Novo Nordisk INC | $172.66 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $143.08 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $130.70 | 2021-2022 | |
| Lilly USA, LLC | $121.11 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $116.33 | 2022 | |
| Exact Sciences Corporation | $113.91 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $101.24 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $90.47 | 2024 | Hetlioz, Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.74 | 2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $59.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $55.61 | 2021-2023 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $47.89 | 2024 | Minimed 780g |
| Alnylam Pharmaceuticals INC. | $46.97 | 2025 | Givlaari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.10 | 2024-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $39.27 | 2021 | |
| Evoke Pharma, INC. | $39.06 | 2023 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.80 | 2021 | |
| Atricure, INC. | $26.72 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Phathom Pharmaceuticals, INC. | $24.38 | 2024 | Voquezna |
| Alkermes, INC. | $22.49 | 2023 | Lybalvi |
| Boston Scientific Corporation | $17.89 | 2024 | Bodyguardian |
| Xeris Pharmaceuticals, INC. | $14.93 | 2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $14.71 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.